Incidence and prevalence of multiple sclerosis during eras of evolving diagnostic criteria—a nationwide population-based registry study over five decades




Maunula, Anna; Laakso, Sini M; Viitala, Matias; Soilu-Hänninen, Merja; Sumelahti, Marja-Liisa; Atula, Sari

PublisherSAGE Publications

THOUSAND OAKS

2025

Multiple Sclerosis Journal - Experimental, Translational and Clinical

Multiple Sclerosis Journal – Experimental, Translational and Clinical

MULT SCLER J-EXP TRA

20552173251326173

11

1

9

2055-2173

DOIhttps://doi.org/10.1177/20552173251326173

https://doi.org/10.1177/20552173251326173

https://research.utu.fi/converis/portal/detail/Publication/491650122



Background: Impact of changing diagnostic criteria for the population-based incidence of multiple sclerosis (MS) has not been investigated.

Objective: To assess the effect of changing diagnostic criteria on national MS incidence and prevalence in Finland from 1974 to 2021.

Methods: We identified patients with MS (pwMS) through the National MS registry and the national Care Register for Healthcare and divided them into four groups based on the year of MS diagnosis: 1) Schumacher criteria (1974-1982), 2) Poser criteria (1983-2000), 3) Earlier McDonald criteria (2001-2016), and 4) Current McDonald criteria (2017-2021). Age-adjusted incidence and prevalence were calculated.

Results: Age-adjusted incidence per 105 person years increased from 3.7 (95% CI 3.5-3.8) during the Schumacher criteria period to 9.2 (95% CI 9.0-9.4) during the earlier McDonald criteria. During the Current McDonald criteria incidence stabilized to 8.6 (95% CI 8.3-9.0). Prevalence increased from 24.3 (95% CI 22.8-25.8) to 241.5 (95% CI 237.3-245.6) per 105 person years.

Conclusion: Both incidence and prevalence of MS increased significantly. Incidence showed a sharp increase when entering the twenty-first century, after which it stabilized. Increasing incidence was likely related to incorporation of MRI in the diagnostic criteria. Current diagnostic criteria did not further increase the incidence.


The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Anna Maunula: Finska Läkaresällskapet, Research Funding of the State of Finland governed through HUS Neurocenter. Matias Viitala: Funding of the State of Finland governed through Helsinki University Hospital. Merja Soilu-Hänninen Funding of the State of Finland governed through Neurocenter, Turku University Hospital.


Last updated on 2025-05-05 at 12:20